GUIDELINES IN FOCUS

Treatment of medulloblastoma in children and adolescents

TRATAMENTO DO MEDULOBLASTOMA EM CRIANÇAS E ADOLESCENTES

Authorship: Sociedade Brasileira de Neurocirurgia
Participants: Nelci Zanon Collange, Silvana de Azevedo Brito, Ricardo Rezende Campos, Egmond Alves Silva Santos, Ricardo Vieira Botelho

Conflict of interest: none

The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize procedures to assist the reasoning and decision-making of doctors.
The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.

INTRODUCTION

Medulloblastoma is the most common brain tumor in children from zero to four years old. It is rare in adults and 75% of cases occur in patients younger than 16 years. Treatment includes surgery, chemo and radiotherapy. Controversy persists about the need for full withdrawal, need and indication of reoperation for residual lesion, the role of neuraxial chemotherapy and radiotherapy, and best treatment of hydrocephalus, which often accompanies these tumors.

This guideline is addressed to physicians, health managers and decision makers in the treatment of this disease.

The guideline was based on clinical issues that were specified for the type of patient, and the method of development for this guideline included the databases that were searched, the electronic search strategy, types of study under evaluation, and the criteria used to produce recommendation. The clinical issues were defended by the authors (group of neurosurgeons of the Pediatric Neurosurgery Department, Sociedade Brasileira de Neurocirurgia – Brazilian Society of Neurosurgery). The electronic search strategies for each clinical question are described in Annex I. The references obtained in the primary studies were evaluated in search of other work, as well as works of knowledge of the authors of the guideline.

The correspondence between the degree of recommendation and the strength of scientific evidence is described after extracting data of each work (in parentheses), and was classified as follows:

A. Experimental or observational studies of higher consistency.
B. Experimental or observational studies of lower consistency.
C. Case reports and non-controlled studies.
D. Opinions without critical evaluation, based on consensus, physiological studies, or animal models.

Size and direction of the effect, benefits, side effects and risks were considered to develop these recommendations.

Method

Patients for whom the guideline was constructed are children, adolescents and young adults aged between 0-18 years with diagnosis of medulloblastoma.

The methods for developing this guideline were those involved in evidence-based medicine, establishing primary trials as the studies with the best quality of existing information for decision making.

Databases searched included the Medline, 1966 to 2013, and the Central Cochrane Register of Controlled Trials, using the terms of the standard vocabulary (MESH) and terms from the text: The references obtained in the primary studies were evaluated in search of other work, as well as works of knowledge of the authors of the guideline.

The correspondence between the degree of recommendation and the strength of scientific evidence is described after extracting data of each work (in parentheses), and was classified as follows:

A. Experimental or observational studies of higher consistency.
B. Experimental or observational studies of lower consistency.
C. Case reports and non-controlled studies.
D. Opinions without critical evaluation, based on consensus, physiological studies, or animal models.

To define the best alternatives for diagnosis and treatment of medulloblastoma in children and adolescents, and recommend them where possible.
**Clinical Questions**

1. **What is the natural history of medulloblastoma in children and adolescents?**

   The search strategy is described in Annex I. There are few articles describing its natural history. The electronic search found 22 publications, whose final evaluation revealed two papers describing the natural history in adults and two in children. Three other works derived from the study of references and knowledge of the authors.

Data extraction

- **Importance of the age:** Among children and adolescents with medulloblastoma, children under three years of age have worse prognosis than those older than that.3
- **Degree of tumor differentiation:** The degree of differentiation of tumor tissue is important for survival. In one study, patients with 90% or more of undifferentiated total tumor tissue exhibited extremely poor prognosis (with none of the nine patients operated remaining alive after 3 years) in contrast with 60% survival in patients with tumors that showed levels of differentiation below 90%.3 (C)
- **Disease-free interval after treatment:** After treatment, disease-free survival at 5 years reached 54% in one study.2 (C) Tumor recurrence, if any, occurs before eight years of treatment.

Severity of hydrocephalus, size of the tumor, and presence of brain-stem invasion were not correlated with prognosis.(D),(C),4(C) (C)

**Recommendation**

It is recommended to consider the medulloblastoma as serious illness. In children under 3 years with undifferentiated tumors, survival is lower. Children older than 3 years with less anaplastic tumors have better survival rates. (C)

2. **Is complete resection of medulloblastoma required?**

   Studies comparing partial and complete resections were evaluated. The search strategy was described in Annex I. 960 articles were found from the electronic search. Of these, 12 articles were initially selected based on the title. Seven articles were selected based on summaries. The Solheim article was excluded as it describes comparisons of mortality among regions in the same country.

Data extraction

Lang et al.7 (C) published a series of cases with retrospective analysis in children older than six months with brain tumor. There were four patients with primitive neuroectodermal tumors/medulloblastoma. There were two intraoperative deaths among 16 cases operated. Of the 14 survivors, four had total resections. One patient with medulloblastoma underwent complete resection (>90%) and was treated with chemotherapy and radiotherapy. Survival lasted 1.2 years and, in terms of neurological status, psychomotor development was impaired, the child was not able to crawl or stand, could speak a few words, and did not present neuropsychological improvements during development. Another patient was operated at the age of 1.4 months, survived for six months and underwent ventriculoperitoneal shunt as adjunctive therapy only. The authors describe four cases of medulloblastoma in the series but the result of only two of the patients.

Raimondi and Tomita8 (C) studied 22 patients. Complete resection was performed in 13 patients, while nine underwent subtotal resection. By then, the patients were studied by CT scans and myelogram. All the patients treated with complete resection were alive at the time when these results were published, as well as 3 out of 9 who underwent partial resection. They all underwent radiotherapy.

Wang et al.9 (C) conducted a retrospective study of 52 patients for analysis of prognostic factors. The results of univariate analysis showed that the greater the extent of resection, the better the prognosis. In multivariate analysis, the extent of resection had no significance.

Monteith et al.10 (C) studied a series of 166 cases of brain tumor in children. Thirty-six cases were medulloblastoma and were sorted according to the extent of resection: Complete resection, 16 cases; incomplete resection, 14 cases; biopsy, six cases. Patients with complete resection of medulloblastoma had higher survival than those undergoing incomplete resection and/or biopsy.

**Recommendation**

There is evidence (C) that complete resection improves survival. Complete resection is recommended wherever possible.

3. **When does the residual tumor, in medulloblastoma, need to be operated after the first surgery?**

124 articles potentially related to our research were identified. Ten were initially selected based on title and summary.10,20 No article specifically investigated the effect of reoperation on residual tumor.
The effect of reoperation in case of residual tumor after surgery needs to be studied.

4. What is the incidence of hydrocephalus in medulloblastoma?
Due to the fact that different types of tumor, presenting medial or lateral location, produce different incidences of hydrocephalus and different outcomes in terms of relief of cerebrospinal fluid flow blockage after tumor resection, we only used studies that exclusively addressed medulloblastomas or allowed evaluating the data separately for each type of tumor.

Data extraction
Kombogiorgas, Hoffman and Muzundar studied specific series of medulloblastoma. Muzundar, in a series of 154 patients (2001-2010), found hydrocephalus in 96.5% of cases. Kombogiorgas, in 2008, found 100% of hydrocephalus in 20 patients, while Hoffman, in a series of 44 patients, observed hydrocephalus in 93.18% of patients. The three studies yielded an average of 96.56% of hydrocephalus in patients with medulloblastoma.

5. What is the effect of tumor resection for the resolution of hydrocephalus?

- Due-Tønnessen and Helseth needed cerebrospinal fluid shunt in 53% of resected medulloblastomas.
- Kombogiorgas, in 2008, operated 20 patients with medulloblastoma with 4 requiring shunt (20%).
- Gopalakrishnan et al. showed that 36.8% of 38 patients with medulloblastoma required CSF shunt.
- Kumar et al. showed that 22.72% of their patients needed post-operative shunt. Seven out of the 55 patients undergoing total resection required CSF shunt (12.7%), compared with 13 of the 33 treated with partial resection (39.3%).
- Morelli had 6 out of 27 patients operated for medulloblastoma (22.22%) requiring CSF shunt.
- Lee et al. studied 42 patients and found a need for CSF shunt in 17 (40%).

The average need for CSF shunt after tumor resection was 32.45% (20 to 53%). Tumor resection treats the associated hydrocephalus in 67.55% of cases.

Recommendation
Tumor removal is recommended for the treatment of hydrocephalus.

6. What is the effect of endoscopic third ventriculostomy in hydrocephalus associated with medulloblastoma compared with ventriculoperitoneal shunt?
The electronic search is described in Annex I. 64 studies were retrieved, but only one by El-Ghandour compared endoscopic third ventriculostomy (ETV) and ventriculoperitoneal shunt (VPS) in the treatment of pediatric patients with severe obstructive hydrocephalus due to tumors in the posterior fossa in 53 cases (32 medulloblastomas).

Data extraction
In the third-ventriculostomy group, complications occurred in three patients (two intraoperative bleeding, and one case of cerebrospinal fluid leaks), while the CSF shunt group, complications occurred in six patients (shunt infection in two cases, with one death; subdural collection in two cases; epidermal hematoma in one case; and upward herniation in one case). Endoscopic third ventriculostomy required less surgical time compared with ventriculoperitoneal shunt (15 min vs. 35 min).

Data from a single non-randomized study with no major differences in complications between the groups (6 vs. 3) do not allow us to assert the superiority of one method or another.

Recommendation
Third-ventriculostomy and ventriculoperitoneal shunt are options in the treatment of hydrocephalus persisting after surgical removal of medulloblastoma.

7. The use of radiotherapy is needed in medulloblastoma?
A study by Bouffet, performed in 1992, postponed radiation only in the supratentorial area and kept RxT in the posterior fossa and spinal cord. Patients had relapsed medulloblastoma in the supratentorial area. Based on this study, radiation therapy has been performed in medulloblastoma to prevent recurrence.

Recommendation
Supra- and infratentorial radiotherapy is recommended to treat children with medulloblastoma (aged 3 years or younger).

8. Should radiotherapy be given to children under 3 years?
Lafay-Cousin et al. studied 29 patients with medulloblastoma aged three years or younger, comparing the
use of conventional craniospinal radiotherapy (group treated before 1994) with radiation therapy only in case of relapse or disease progression. The group receiving conventional radiotherapy showed significant lowering of intellectual and academic performance compared with the group in which radiotherapy was delayed. Radiotherapy has been avoided in children under 3 years old.32

Recommendation
Radiotherapy should be avoided or used only in cases of relapse or lack of tumor control in order to prevent intellectual deficit. (B)

ANNEX I: SEARCH STRATEGIES AND NUMBER OF STUDIES INITIALLY RETRIEVED FROM THE ELECTRONIC SEARCH

Search strategy: Natural history

Search strategy: Effect of the extension of tumor resection

Search strategy: Reoperation in the presence of residual tumor after surgery

Search strategy: Comparison of tumor removal, third-ventriculostomy, and CSF shunt to treat hydrocephalus

Search strategy: What is the effect of endoscopic third ventriculostomy in hydrocephalus associated with medulloblastoma compared with ventriculoperitoneal shunt?

Search strategy: Is it necessary to use radiotherapy in medulloblastoma?

Search strategy: What is the effect of radiotherapy in children under 3 years old?

REFERENCES